BACKGROUND: The aim of this work was to study the expression of alpha, beta1, and beta4 integrin subunits in meningiomas. METHODS: Seventeen atypical or anaplastic meningiomas were retrieved from the files of Hôpital de Bellevue, Saint-Etienne, France. They were compared with 17 benign meningiomas consecutively examined in 1997 and 6 schwannomas. The tumors were classified according to standard histologic criteria. Frozen sections were immunostained for alpha1, alpha2, alpha3, alpha4, alpha5, alpha6, beta1, and beta4 integrin subunits; collagen; laminin and fibronectin; cytokeratin; vimentin; neural cell adhesion molecule (NCAM); and MIB-1. RESULTS: The study included 7 fibrous meningiomas, 6 transitional meningiomas, 19 syncytial meningiomas, and 2 secretory meningiomas. The expression of alpha1, alpha3, alpha5, alpha6, and beta1 was constant. The expression of alpha1 was higher in fibrous meningiomas than in syncytial meningiomas. Only in transitional, syncytial, and secretory meningiomas was the expression of alpha2 detected. The expression of alpha2 and beta4 was associated with the expression of cytokeratin in the glandular structures of secretory meningiomas, whereas it was associated with NCAM expression in the whorls of meningothelial meningiomas. The expression of integrin receptors by tumor cells was strongly correlated with that of their respective ligands in the extracellular matrix. In invasive meningiomas, the expression of alpha3 and alpha6 by tumor cells was significantly lower. The higher the MIB-1 proliferation index, the lower the expression of alpha3. The 6 schwannomas expressed only alpha2, alpha3, alpha6, beta1, and beta4 integrins. CONCLUSIONS: Each histologic subtype of meningioma has a specific spectrum of integrin expression. The study of alpha3 and alpha6 may have prognostic value in the assessment of meningiomas. The study of the integrin profile is valuable for the differential diagnosis of fibrous meningiomas and schwannomas. Copyright 1999 American Cancer Society.
BACKGROUND: The aim of this work was to study the expression of alpha, beta1, and beta4 integrin subunits in meningiomas. METHODS: Seventeen atypical or anaplastic meningiomas were retrieved from the files of Hôpital de Bellevue, Saint-Etienne, France. They were compared with 17 benign meningiomas consecutively examined in 1997 and 6 schwannomas. The tumors were classified according to standard histologic criteria. Frozen sections were immunostained for alpha1, alpha2, alpha3, alpha4, alpha5, alpha6, beta1, and beta4 integrin subunits; collagen; laminin and fibronectin; cytokeratin; vimentin; neural cell adhesion molecule (NCAM); and MIB-1. RESULTS: The study included 7 fibrous meningiomas, 6 transitional meningiomas, 19 syncytial meningiomas, and 2 secretory meningiomas. The expression of alpha1, alpha3, alpha5, alpha6, and beta1 was constant. The expression of alpha1 was higher in fibrous meningiomas than in syncytial meningiomas. Only in transitional, syncytial, and secretory meningiomas was the expression of alpha2 detected. The expression of alpha2 and beta4 was associated with the expression of cytokeratin in the glandular structures of secretory meningiomas, whereas it was associated with NCAM expression in the whorls of meningothelial meningiomas. The expression of integrin receptors by tumor cells was strongly correlated with that of their respective ligands in the extracellular matrix. In invasive meningiomas, the expression of alpha3 and alpha6 by tumor cells was significantly lower. The higher the MIB-1 proliferation index, the lower the expression of alpha3. The 6 schwannomas expressed only alpha2, alpha3, alpha6, beta1, and beta4 integrins. CONCLUSIONS: Each histologic subtype of meningioma has a specific spectrum of integrin expression. The study of alpha3 and alpha6 may have prognostic value in the assessment of meningiomas. The study of the integrin profile is valuable for the differential diagnosis of fibrous meningiomas and schwannomas. Copyright 1999 American Cancer Society.
Authors: Preetha Rajaraman; Alina V Brenner; Gila Neta; Ruth Pfeiffer; Sophia S Wang; Meredith Yeager; Gilles Thomas; Howard A Fine; Martha S Linet; Nathaniel Rothman; Stephen J Chanock; Peter D Inskip Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-04-20 Impact factor: 4.254
Authors: Fares Nigim; Juri Kiyokawa; Alessandra Gurtner; Yoichiro Kawamura; Lingyang Hua; Ekkehard M Kasper; Priscilla K Brastianos; Daniel P Cahill; Samuel D Rabkin; Robert L Martuza; W Shawn Carbonell; Hiroaki Wakimoto Journal: Target Oncol Date: 2019-08 Impact factor: 4.493
Authors: Marianne F James; Johanna M Lelke; Mia Maccollin; Scott R Plotkin; Anat O Stemmer-Rachamimov; Vijaya Ramesh; James F Gusella Journal: Neurobiol Dis Date: 2007-09-19 Impact factor: 5.996
Authors: Matthew N Svalina; Ken Kikuchi; Jinu Abraham; Sangeet Lal; Monika A Davare; Teagan P Settelmeyer; Michael C Young; Jennifer L Peckham; Yoon-Jae Cho; Joel E Michalek; Brian S Hernandez; Noah E Berlow; Melanie Jackson; Daniel J Guillaume; Nathan R Selden; Darell D Bigner; Kellie J Nazemi; Sarah C Green; Christopher L Corless; Sakir Gultekin; Atiya Mansoor; Brian P Rubin; Randall Woltjer; Charles Keller Journal: Sci Rep Date: 2016-06-03 Impact factor: 4.379